hit counter
BioCryst Pharmaceuticals, Inc. (BCRX) Stock News Sentiment & Price - Sentifly
BCRX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BioCryst Pharmaceuticals, Inc. (BCRX)

USA
Biotechnology
NASDAQ
BCRX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BCRX Latest news
GlobeNewsWire
Neutral
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
2021-11-05 07:00

Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic therapies Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic therapies

Seeking Alpha
Neutral
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript
2021-11-03 15:07

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript

The Motley Fool
Negative
Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
2021-11-03 13:13

The biotech's third quarter was a good one, once you look past the top-line numbers.

Zacks Investment Research
Positive
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
2021-11-03 09:58

BioCryst (BCRX) delivered earnings and revenue surprises of -10.00% and 8.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
2021-11-03 07:00

—3Q 2021 revenue of $41.0 million—

Zacks Investment Research
Negative
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
2021-10-27 16:11

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2021-10-26 07:00

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts, including one Distinguished Industry Oral Abstract, on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place in New Orleans, Louisiana, and online, from November 4-8, 2021.

GlobeNewsWire
Neutral
BioCryst to Report Third Quarter 2021 Financial Results on November 3
2021-10-20 07:00

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021.

InvestorPlace
Positive
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
2021-10-18 13:42

These growth stocks could become multi-baggers in the future. Investors should consider them as they start to move at an aggressive pace.

The Motley Fool
Positive
2 Super-Charged Growth Stocks to Buy Now
2021-10-13 10:00

These two small drugmakers are poised for a long-winded growth spurt.

Loading more news...